Bicalutamide versus spironolactone for hair loss: counts and visible change

If a dermatologist suggests replacing spironolactone with bicalutamide, ask what improvement would justify the change: a measurement at one scalp spot, a photograph you can distinguish from baseline, or less shedding when you wash your hair. Those are different treatment goals.

What the comparison measured

A double-blind Indian trial randomized 204 women aged 18–50 with female pattern hair loss to daily bicalutamide 50 mg or spironolactone 100 mg, each used alone for 24 weeks. Of these, 188 completed treatment.¹

At the frontal measurement site, average gains were 5.05 versus 3.13 hairs/cm², favoring bicalutamide by 1.92 hairs/cm². At the vertex, the between-group advantage was 3.26 hairs/cm², with a 95% confidence interval of 0.35–6.08.¹

The authors found no statistically significant between-group differences in clinical endpoints, which included global photographs and shedding scores. Better magnified counts therefore did not establish a clinical advantage at this assessment.¹

The single-center, per-protocol analysis does not establish longer-term results or outcomes beyond age 50.¹

A count advantage does not settle prescribing

The U.S. bicalutamide label, revised September 2025, lists women among its contraindications and says it can cause fetal harm. Its approved indication is metastatic prostate cancer in combination with another hormone treatment. Hair-loss prescribing requires a discussion of that regulatory position.²

The label also reports severe liver injury, including fatal cases. It calls for liver enzyme tests before treatment, regularly during the first four months, and periodically thereafter. Liver monitoring remains part of the prescribing discussion.²

Spironolactone has its own suitability questions. The American Academy of Dermatology’s patient guidance, last updated December 2022, asks patients to disclose kidney or adrenal conditions and all medicines and supplements before taking it. It identifies minoxidil as the most recommended treatment for female pattern hair loss and warns against prescription hair-loss medicines during pregnancy or when planning pregnancy.³

Define the result before switching

Bring the same dated scalp photographs to the prescribing appointment. Ask: “What would make you recommend a switch rather than continuing my current treatment? Which result will we compare, and when?” If a clinic plans to use magnified counts, ask whether it will also compare your overall photographs and your own treatment goal.

Our spironolactone prescribing guide covers its monitoring discussion. Hair, Everywhere includes a Hair Log and a chapter on treatment evidence, timelines and off-label prescriptions. Use the log to keep the start date, assessment date and photographs together.